SCHEMBL5481932

SCHEMBL5481932

Nc1cccc(-c2cn3ccnc3c(-n3ccnc3-c3ccncc3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.50
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
GFER P55789 1/20 0.49
SYK P43405 2/20 0.48
CD63 P08962 1/20 0.48
PIK3R1 P27986 2/20 0.45
PIK3CA P42336 2/20 0.45
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPK9 P45984 1/20 0.42
MAPK10 P53779 1/20 0.42
EPHB4 P54760 10/20 0.41
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5477740 0.93 AURKA (0.52) AURKAALDH1A1POLBGFERSYK
SCHEMBL4803454 0.77 ALDH1A1 (0.59) AURKAALDH1A1POLBGFERSYK
SCHEMBL5474690 0.76 EPHB4 (0.64) SYKEPHB4
SCHEMBL5481710 0.76 HTR2C (0.48) AURKAPIK3R1PIK3CALMNAMAPK9
SCHEMBL5474686 0.76 AURKA (0.50) AURKAALDH1A1POLBGFERSYK
SCHEMBL5481701 0.75 AURKA (0.50) AURKAALDH1A1POLBGFERSYK
SCHEMBL14431283 0.75 EPHB4 (0.60) AURKAALDH1A1POLBGFERSYK
SCHEMBL5479039 0.73 EPHB4 (0.73) SYKEPHB4
SCHEMBL5477799 0.72 BTK (0.61) AURKAALDH1A1POLBGFERSYK
SCHEMBL5488997 0.72 EPHB4 (0.72) SYKEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189723-B2 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed
US-7189723-B2 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed
US-20050054648-A1 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity GILEAD CONNECTICUT, INC. 2005-03-10 US disclosed
WO-2004072081-A1 CERTAIN 8-HETEROARYL-6-PHENYL-IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS, INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054648-A1 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity EPHB1, EPHB4, EPHB2 AURKA 368/4885ALDH1A1 782/4885POLB 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.